Repurposing the KCa3.1 Blocker Senicapoc for Ischemic Stroke
Translational Stroke Research · 2024
DOI: 10.1007/s12975-023-01152-6 ↗Kurz gefasst
Fachartikel in der Zeitschrift Translational Stroke Research, 2024. Verfasst von Ruth D Lee und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, School of Medicine, University of California, Davis, CA, 95616, USA. Hauptthemen laut MEDLINE: Intermediate-Conductance Calcium-Activated Potassium Channels, Ischemic Stroke, Mice, Inbred C57BL. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NINDS NIH HHS, National Institute of Neurological Disorders and Stroke.
Themen: Schlaganfall
Abstract (Originalsprache)
Senicapoc, a small molecule inhibitor of the calcium-activated potassium channel KCa3.1, was safe and well-tolerated in clinical trials for sickle cell anemia. We previously reported proof-of-concept data suggesting that both pharmacological inhibition and genetic deletion of KCa3.1 reduces infarction and improves neurologic recovery in rodents by attenuating neuroinflammation. Here we evaluated the potential of repurposing senicapoc for ischemic stroke. In cultured microglia, senicapoc inhibited KCa3.1 currents with an IC 50 of 7 nM, reduced Ca 2+ signaling induced by the purinergic agonist ATP, suppressed expression of pro-inflammatory cytokines and enzymes (iNOS and COX-2), and prevented induction of the inflammasome component NLRP3 . When transient middle cerebral artery occlusion (tMCAO, 60 min) was induced in male C57BL/6 J mice, twice daily administration of senicapoc at 10 and 40 mg/kg starting 12 h after reperfusion dose-dependently reduced infarct area determined by T2-weighted magnetic resonance imaging (MRI) and improved neurological deficit on day 8. Ultra-high-performance liquid chromatography/mass spectrometry analysis of total and free brain concentrations demonstrated sufficient KCa3.1 target engagement. Senicapoc treatment significantly reduced microglia/macrophage and T cell infiltration and activation and attenuated neuronal death. A different treatment paradigm with senicapoc started at 3 h and MRI on day 3 and day 8 revealed that senicapoc reduces secondary infarct growth and suppresses expression of inflammation markers, including T cell cytokines in the brain. Lastly, we demonstrated that senicapoc does not impair the proteolytic activity of tissue plasminogen activator (tPA) in vitro. We suggest that senicapoc could be repurposed as an adjunctive immunocytoprotective agent for combination with reperfusion therapy for ischemic stroke.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, School of Medicine, University of California, Davis, CA, 95616, USA.
- Animal Models Core, Department of Pharmacology, School of Medicine, University of California, Davis, CA, 95616, USA.
- Department of Neurology, School of Medicine, University of Washington, Seattle, WA, 98195, USA.
- Department of Pharmacology, School of Medicine, University of California, Davis, CA, 95616, USA. hwulff@ucdavis.edu.
Förderung
- NINDS NIH HHS
- National Institute of Neurological Disorders and Stroke
Zitieren
APA
Lee, R. D., Chen, Y. J., Nguyen, H. M., Singh, L., Dietrich, C. J., Pyles, B. R., Cui, Y., Weinstein, J. R., & Wulff, H. (2024). Repurposing the KCa3.1 Blocker Senicapoc for Ischemic Stroke. Translational Stroke Research. https://doi.org/10.1007/s12975-023-01152-6
Vancouver
Lee RD, Chen YJ, Nguyen HM, Singh L, Dietrich CJ, Pyles BR, et al. Repurposing the KCa3.1 Blocker Senicapoc for Ischemic Stroke. Translational Stroke Research. 2024. doi:10.1007/s12975-023-01152-6
BibTeX
@article{Lee2024,
author = {Lee, Ruth D and Chen, Yi-Je and Nguyen, Hai M and Singh, Latika and Dietrich, Connor J and Pyles, Benjamin R and Cui, Yanjun and Weinstein, Jonathan R and Wulff, Heike},
title = {Repurposing the KCa3.1 Blocker Senicapoc for Ischemic Stroke},
journal = {Translational Stroke Research},
year = {2024},
doi = {10.1007/s12975-023-01152-6}
}
EUVIMED